Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
暂无分享,去创建一个
N. Fleshner | A. Kapoor | U. Emmenegger | P. Zalewski | Cameron M Phillips | Juan Briones | Amanjot K. Sidhu | Nabeeha Khan | Edward Chow
[1] O. Sartor. Circulating tumor DNA biomarkers for response assessment in prostate cancer. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] A. Armstrong,et al. The Value of Phenotypic Precision Medicine in Prostate Cancer , 2022, The oncologist.
[3] H. Minn,et al. Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study , 2022, Cancer medicine.
[4] J. Ferlay,et al. Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.
[5] P. Caroli,et al. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging , 2021, Therapeutic advances in medical oncology.
[6] G. Sonpavde,et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. , 2020, Critical reviews in oncology/hematology.
[7] G. Tortora,et al. Biomarkers of response to advanced prostate cancer therapy , 2020, Expert review of molecular diagnostics.
[8] Liying Zhang,et al. Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome , 2019, Cancer management and research.
[9] T. Todenhöfer,et al. Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review , 2019, The world journal of men's health.
[10] P. Friedl,et al. Radium 223-mediated zonal cytotoxicity of prostate cancer in bone. , 2019, Journal of the National Cancer Institute.
[11] H. Macapinlac,et al. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[12] O. Sartor,et al. Metastatic Prostate Cancer. , 2018, The New England journal of medicine.
[13] S. Tyldesley,et al. A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[14] M. Kattan,et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] K. Tabata,et al. Prostate‐Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy‐Naive Patients With Metastatic Castration‐Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.
[16] R. Vessella,et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models , 2017, Clinical Cancer Research.
[17] M. Shiota,et al. Co‐introduction of a steroid with docetaxel chemotherapy for metastatic castration‐resistant prostate cancer affects PSA flare , 2016, BJU international.
[18] E. Heath,et al. Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. , 2016, Clinical genitourinary cancer.
[19] M. Liberatore,et al. Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report. , 2016, Clinical genitourinary cancer.
[20] F. Saad,et al. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. , 2015, European urology.
[21] D. George,et al. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report , 2015, BMC Cancer.
[22] S. Fosså,et al. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223 , 2015, Scandinavian journal of urology.
[23] S. Oudard,et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.
[24] S. Hong,et al. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis , 2014, Journal of Cancer Research and Clinical Oncology.
[25] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[26] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[27] A. Lipton. Implications of bone metastases and the benefits of bone-targeted therapy. , 2010, Seminars in oncology.
[28] T. Nelius,et al. PSA surge/flare‐up in patients with castration‐refractory prostate cancer during the initial phase of chemotherapy , 2009, The Prostate.
[29] C. Sternberg,et al. Prostate‐specific antigen flare phenomenon with docetaxel‐based chemotherapy in patients with androgen‐independent prostate cancer , 2008, BJU international.
[30] Elizabeth Garrett-Mayer,et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Tangen,et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.
[32] M. Naoe,et al. INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER. , 2016, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[33] T. Klatte,et al. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy , 2007, International Urology and Nephrology.